Reata Pharmaceuticals
RETA
RETA was delisted on the 25th of September, 2023.
42 hedge funds and large institutions have $106M invested in Reata Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
38.73% more ownership
Funds ownership: 0% → 38.73% (+39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Novo Holdings A/S
Hellerup,
Denmark
|
+$65.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7M |
| 3 |
JP Morgan Chase
New York
|
+$4.72M |
| 4 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$3.55M |
| 5 |
Emerald Advisers
Leola,
Pennsylvania
|
+$3.26M |
Top Sellers
RETA Hedge Fund Activity: Q2 2016 in Review
42 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals (RETA) for Q2 2016, worth a combined $106M.
Buyers outnumbered sellers: 42 funds opened new RETA positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $65.5M.
- 42 institutional investors held Reata Pharmaceuticals (RETA) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $106M of Reata Pharmaceuticals stock for Q2 2016.
- 42 funds opened new Reata Pharmaceuticals positions in Q2 2016 and 0 closed out, a net change of +42 holders.
- The largest Reata Pharmaceuticals buyer in Q2 2016 was Novo Holdings A/S, an estimated $65.5M added.
Based on aggregated 13F filings for Q2 2016.